X
Details:
Product characterization is an important next step for RSBT-001 before filing an Investigational New Drug (IND) application with the FDA for the treatment of chronic obstructive pulmonary disease (COPD).
Lead Product(s): RSBT-001
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RSBT-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: RS BioTherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 14, 2022
Mecce 2023
Not Confirmed
Contact SupplierDetails:
Recipharm is developing and commercializing inhalation technologies and products in support of the development and advancement of Transpire Bio’s TRB-1 and TRB-2 respiratory products.
Lead Product(s): TRB-1
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TRB-1
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Transpire Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 14, 2022
Mecce 2023
Not Confirmed
Contact SupplierDetails:
The acquisition of Recipharm, to provide innovative drug developers in the Biologics market with differentiated contract development and manufacturing services for ATMPs and builds on the capabilities acquired through GenIbet transaction and acquisition of Vibalogics.
Lead Product(s): Microbiome Therapeutic
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Recipient: Arranta Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 18, 2022
Mecce 2023
Not Confirmed
Contact SupplierDetails:
Recipharm has reserved capacity to support the anticipated demand for the mRNA-1273 vaccine and is already in the process of recruiting additional staff and making certain investments to enable technology transfer and scale-up to commence imminently.
Lead Product(s): mRNA-1273
Therapeutic Area: Infections and Infectious Diseases Product Name: mRNA-1273
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 24, 2020
Mecce 2023
Not Confirmed
Contact Supplier
Details:
The study indicates that patients taking Erdosteine after hospital discharge benefit significant improvements in health-related quality of life parameters (HRQoL) and dyspnoea. This study is one of the first to report HRQoL details in patients with COVID-19.
Lead Product(s): Erdosteine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2020
Mecce 2023
Not Confirmed
Contact SupplierDetails:
Arcturus has secured manufacturing slots with Recipharm to support the manufacture of ARCT-021, Arcturus’ COVID-19 vaccine candidate that is in an ongoing phase 1/2 clinical trial.
Lead Product(s): ARCT-021
Therapeutic Area: Infections and Infectious Diseases Product Name: LUNAR-COV19
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Arcturus Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 06, 2020
Mecce 2023
Not Confirmed
Contact SupplierDetails:
The new agreement provides both companies with a long-term partnership that will ensure continued supply for patients across the globe. Opicapone (Ongentys) is approved in Europe, USA, South Korea, Taiwan, Australia and Japan.
Lead Product(s): Opicapone
Therapeutic Area: Neurology Product Name: Ongentys
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bial
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 01, 2020
Mecce 2023
Not Confirmed
Contact SupplierDetails:
Under the contract, Vibalogics will produce multiple batches of the vaccine candidate at its facility in Cuxhaven, Germany, expected to yield thousands of vaccine doses.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Recipharm has the brightest minds in the CDMO industry, from early development to commercial manufacturing.
